secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001628280-26-007673
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M
----------------------------------------------------------------

- Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).
- Q4 net loss $16.3M vs $49.0M loss YoY; FY25 net loss $43.5M vs $182.6M loss YoY.
- Operating expenses down 18% Q4 and 17% FY; gross margin 68% Q4 and 69% FY.
- FY2026 revenue guidance $600-625M (0-4% growth ex-2025 settlements).
- Cash and equivalents $523.4M at year-end, up $130M vs prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000162828026007673/0001628280-26-007673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000162828026007673/txg-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-007673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer